Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 ...

Ultragenyx recently resubmitted a BLA seeking approval for the gene therapy after the FDA rejected it, and the firm will resubmit it again in response to new questions.

NEW YORK – The US Food and Drug Administration on Wednesday said that the intravenous or subcutaneous versions of Merck's checkpoint inhibitor can be combined with standard treatment and given to ...

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at ...

NEW YORK – Tempest Therapeutics on Wednesday said it plans to prioritize development of its newly acquired CAR T-cell therapy programs, TPST-2003 and TPST-4003, while seeking external partners for its ...

Gilead's other CAR-T therapies also performed poorly over the same period. In Q5 2025, Yescarta sold $368 million, down 6 ...

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.

Researchers are evaluating Lyell's CD19/20 dual-targeting CAR-T against marketed CD19 CAR T-cell therapies in the second-line refractory large B-cell lymphoma setting.

Vertex posted revenue and earnings for Q4 and full-year 2025 that hovered around consensus Wall Street estimates, but CRISPR Therapeutics missed expectations.

NEW YORK – Yatiri Bio's artificial intelligence-based proteomic platform is giving new hope to a SMARCA2/4 inhibitor program that Foghorn Therapeutics previously halted. After seeing Yatiri's ability ...